Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Institut de Cancérologie de l’Ouest Angers-Nantes

1 abstract

Abstract
VERITAC-2: A global, randomized phase 3 study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer.
Org: Institut de Cancérologie de l’Ouest Angers-Nantes, Washington University School of Medicine in St Louis, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Aichi Cancer Center Hospital, UCLA Jonsson Comprehensive Cancer Center,